Eli Lilly
Latest news, explainers and analysis on Eli Lilly. Tracking 2 stories on Arth Vani.
Connected in the graph
Latest on Eli Lilly
BreakingEli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag
Pharmaceutical giant Eli Lilly, driven by the success of Mounjaro and Zepbound, aims to launch up to four new weight-loss products in the coming years. The company acknowledges India's strong biotechnology talent and expertise, but highlights existing challenges in the research funding environment. Eli Lilly has expressed openness to forming partnerships with Indian biotech firms for future collaborations.
Druckenmiller Bets on Rhythm Pharma for Rare Obesity Untouched by Eli Lilly, Novo Nordisk
Billionaire investor Stanley Druckenmiller is reportedly investing in Rhythm Pharmaceuticals, a company focused on treating rare genetic forms of obesity. This move stands apart from the broader market trend, as Rhythm's treatments target conditions not addressed by popular weight-loss drugs from pharmaceutical giants like Eli Lilly and Novo Nordisk. Druckenmiller's strategy highlights a focus on specialized, unmet medical needs within the burgeoning obesity treatment sector.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.